Federal Government’s Potential Green Signal to Cannabis Could Propel Cannabis Stocks

WINDSOR, ON / ACCESSWIRE / June 15, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to discuss four biotech stocks that could see massive upside potential due to developments in the medical marijuana industry.

The legalization trend being witnessed in the US as well as neighboring countries could propel these stocks:

• 22nd
  Century Group Inc. (NYSE MKT: XXII)
• GW
  Pharmaceuticals plc (NASDAQ: GWPH)
• Cannabis
  Science Inc. (OTC MKTS: CBIS)
• Cannabics
  Pharmaceuticals Inc. (OTC MKTS: CNBX)
• Enertopia
  Corp (OTC MKTS: ENRT)

For a glimpse into the kind of surge we’re talking about, let’s have a look at the projections for 22nd Century. Shares were trading at $0.78 on May 5, and Chardan Capital analysts projects the share price to reach $4.50 in less than a year. That’s a return of almost 500%.

Marijuana or cannabis has been known for centuries to treat disease and improve symptoms. The active chemical ingredient in cannabis is called a cannabinoid and there are more than 100 known cannabinoids in the cannabis plant. The two most well-known cannabinoids in marijuana that scientists and researchers believe have numerous medicinal applications are cannabidiol (CBD), which has an impact on the brain, and tetrahydrocannabinol (THC), which has pain relieving properties. The reason modern medicine knows little about the wonder drugs that can be produced from the cannabis plant is because of the Federal ban on marijuana that became effective in the early twentieth century.

Marijuana Regaining Favor

In 1996, California legalized medical cannabis. Over the next two decades, other states followed suit, especially for the legalization of medical marijuana for non-recreational use. With the joining of Pennsylvania earlier this year, 24 states have now legalized use of the marijuana plant for medical purposes.

Also during the course of these two decades, thousands of clinical studies have been conducted to determine the medical uses of cannabis and cannabinoids in different diseases. There is strong evidence of the benefits of medical cannabis in ailments like nausea and vomiting associated with cancer chemotherapy, chronic pain, spasticity in multiple sclerosis, anorexia and cachexia in HIV/AIDS and spinal cord injury.

More recent research has indicated that cannabis helps with epilepsy, pruritus and depression. In March 2016, GW
Pharmaceuticals plc (NASDAQ: GWPH) made a breakthrough in the first pivotal Phase III study of its cannabis-derived epilepsy drug Epidiolex in convulsive seizures.

The primary endpoint was achieved with high statistical significance, indicating that Epidiolex reduced convulsive seizures in children suffering from Dravet syndrome, which is a rare and severe form of epilepsy that currently has no FDA-approved treatment.

What Does It Really Mean

While the medical benefits of marijuana continue to be unfolded, there is immense pressure on the Federal government to legalize marijuana. There has already been some breakthrough in this regard. Prior to December 2015, federal cannabis laws took precedence over the medical marijuana laws passed by various states in the US. This gave federal agents the authority to legally raid medical marijuana dispensaries and seize property even in states where medical cannabis was legal.

With the potential lifting of the federal ban based on momentum gathering from the underlying roll-out of multiple individual states legalizing medical and or recreational, marijuana dispensaries could potentially not longer be under the threat of raids and investigations by federal agents along with a whole host of potential benefits.

Canada is already on the verge, with Prime Minister Justin Trudeau previously announcing that the full legalization of recreational marijuana in Canada is one of his top priorities for Canada, after which Health Minister Jane Philpott has more recently announced that the Canadian government would introduce legislation to legalize recreational marijuana in Spring 2017. Complete legalization in the US is long overdue. This would enable researchers to study the medicinal uses of cannabis in greater depth, and better understand how it impacts the body.

Legalization means so much more to the medical marijuana industry. It would mean no banking restrictions as well as no restrictions on stock exchanges (since these would no longer be illegal businesses). Fewer regulations and increased freedom would greatly boost companies that have cannabis-related products.

Stocks That Could Get High on
Marijuana

Here are four stock ideas that are poised to benefit when from the federal government lifts its ban on marijuana:

22nd Century Group Inc. (NYSE MKT: XXII): The company is engaged in the R&D, licensing, manufacturing, and worldwide sales and distribution of innovative and effective patented products. 22nd Century owns or exclusively controls over 200 issued patents and has more than 50 pending patent applications globally. The company’s proprietary genetic engineering technology and plant breeding expertise enables it to upregulate and downregulate cannabinoids in the cannabis plant. 22nd Century is the only company with patents on the genes that completely eliminate THC in plants, the drug that needs to be eliminated in purely medical varietals and commercial hemp varietals of the plant.

The company also has a strategic partnership with Anandia Labs, a leading player in Canada’s cannabis market. The cannabis research collaboration – where 22nd Century holds exclusive rights in the U.S. to the genes required for cannabinoid production in the cannabis plant – holds the promise of lucrative commercialization opportunities. Through its innovative research, the Company intends to cost-effectively produce commercial quantities of marijuana-based cannabinoids – including CBD and CBC – that show great promise in treating neurological disorders and other medical diseases.

Cannabis Science Inc. (OTC MKTS: CBIS): The company is engaged in R&D in medical marijuana. Cannabis Science uses scientific techniques to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products for critical illnesses. The company aims at developing governmentally approved drugs, including CS-TATI1, CS-S/BCC-1, and patented neurological therapy under study or development.

Cannabics Pharmaceuticals Inc. (OTCMKTS: CNBX): Formerly known as American Mining Company, this is a biotechnology pharmaceutical company focused on development and licensing of cannabinoid-based treatments and therapies. Cannabics Pharma develops and markets various therapies and biotechnological tools aimed at providing relief from ailments that respond to active ingredients sourced from the cannabis plant.

Enertopia Corp (OTCMKTS: ENRT): This is a development-stage company that operates through three segments, namely renewable energy, oil and gas exploration and medical marijuana. Enertopia is seeking to produce, cultivate and distribute medical marijuana in Canada under the new Federal Government of Canada’s Marihuana for Medical Purposes Regulations (MMPR) Program.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.

Follow us on Twitter: @Wealthy_VC

Like us on Facebook: www.facebook.com/WealthyVC

Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. The Wealthy Biotech Trader’s parent company has been and will be compensated $15,000 per month by 22nd Century Group. Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article. The Wealthy Biotech Trader may from time to time outsource copywriting for these articles and does not accept responsibility for mistakes written by 3rd party writers as readers should always verify all statements.

SOURCE: The Wealthy Venture Capitalist

ReleaseID: 441111